QC
ALGS icon

Quadrature Capital’s Aligos Therapeutics ALGS Stock Holding History

Quadrature Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,822
Closed -$80.4K – 1564
2026
Q1 		$80.4K Buy
+10,822
New +$82.1K ﹤0.01% 1251

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital's ALGS Position: Q2 2026 in Review

Quadrature Capital sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 10,822 shares — an estimated $80.4K sold.

Quadrature Capital first reported a position in ALGS in Q1 2026 and held it in 1 quarter. The position peaked at $80.4K in Q1 2026. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Quadrature Capital reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 10,822 Aligos Therapeutics shares in Q2 2026, an estimated $80.4K.
  • Quadrature Capital first reported a position in Aligos Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quadrature Capital's Aligos Therapeutics position peaked at $80.4K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.